Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial

Peer Review reports

Original Submission
18 Nov 2020	Submitted	Original manuscript
6 Feb 2021	Reviewed	Reviewer Report - Kirsty Loudon
7 Feb 2021	Reviewed	Reviewer Report - Michael Joyner
11 Feb 2021	Author responded	Author comments - Benjamin Gaborit
Resubmission - Version 2
11 Feb 2021	Submitted	Manuscript version 2
Publishing
13 Feb 2021	Editorially accepted
9 Mar 2021	Article published	10.1186/s13063-021-05132-9

Back to article page